Kelly K. Hunt

60.8k total citations · 7 hit papers
744 papers, 40.5k citations indexed

About

Kelly K. Hunt is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Kelly K. Hunt has authored 744 papers receiving a total of 40.5k indexed citations (citations by other indexed papers that have themselves been cited), including 442 papers in Cancer Research, 344 papers in Oncology and 293 papers in Pathology and Forensic Medicine. Recurrent topics in Kelly K. Hunt's work include Breast Cancer Treatment Studies (413 papers), Breast Lesions and Carcinomas (261 papers) and Breast Implant and Reconstruction (186 papers). Kelly K. Hunt is often cited by papers focused on Breast Cancer Treatment Studies (413 papers), Breast Lesions and Carcinomas (261 papers) and Breast Implant and Reconstruction (186 papers). Kelly K. Hunt collaborates with scholars based in United States, United Kingdom and Switzerland. Kelly K. Hunt's co-authors include Henry M. Kuerer, Thomas A. Buchholz, Barry W. Feig, Merrick I. Ross, S. Eva Singletary, Gabriel N. Hortobágyi, Elizabeth A. Mittendorf, Gildy V. Babiera, Funda Meric‐Bernstam and Aman U. Buzdar and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Kelly K. Hunt

725 papers receiving 39.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis

2017 1.1k citations Kelly K. Hunt et al. profile →
Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy

1999 1.1k citations Henry M. Kuerer, Terry L. Smith et al. Journal of Clinical Oncology profile →
Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases

2010 879 citations Kelly K. Hunt et al. profile →
Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

2005 867 citations Aman U. Buzdar, Nuhad K. Ibrahim et al. Journal of Clinical Oncology profile →
Surgical Complications Associated With Sentinel Lymph Node Dissection (SLND) Plus Axillary Lymph Node Dissection Compared With SLND Alone in the American College of Surgeons Oncology Group Trial Z0011

2007 660 citations Anthony Lucci, Kelly K. Hunt et al. Journal of Clinical Oncology profile →
Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection

2016 578 citations Abigail S. Caudle, Elizabeth A. Mittendorf et al. Journal of Clinical Oncology profile →
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype

2017 417 citations W. Fraser Symmans, Kelly K. Hunt et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kelly K. Hunt United States	104	24.3k	17.5k	16.1k	13.3k	7.8k	744	40.5k
Stuart J. Schnitt United States	94	15.7k 0.6×	12.2k 0.7×	11.0k 0.7×	5.1k 0.4×	3.4k 0.4×	377	30.5k
Giuseppe Viale Italy	113	26.1k 1.1×	29.3k 1.7×	12.6k 0.8×	8.1k 0.6×	9.5k 1.2×	768	55.3k
Umberto Veronesi Italy	88	21.5k 0.9×	12.4k 0.7×	13.4k 0.8×	9.8k 0.7×	3.0k 0.4×	411	32.1k
Vicente Valero United States	94	13.2k 0.5×	17.3k 1.0×	4.7k 0.3×	2.8k 0.2×	4.9k 0.6×	500	27.9k
Aron Goldhirsch Italy	92	17.2k 0.7×	20.5k 1.2×	6.2k 0.4×	3.0k 0.2×	6.1k 0.8×	491	33.5k
Luigi Mariani Italy	84	8.2k 0.3×	10.6k 0.6×	4.4k 0.3×	7.5k 0.6×	8.8k 1.1×	451	32.0k
Emiel J. Rutgers Netherlands	73	13.1k 0.5×	8.2k 0.5×	7.3k 0.5×	4.5k 0.3×	3.3k 0.4×	467	21.4k
Paolo Veronesi Italy	74	12.9k 0.5×	7.3k 0.4×	8.3k 0.5×	7.4k 0.6×	3.5k 0.4×	457	20.1k
Edwin R. Fisher United States	73	22.3k 0.9×	17.0k 1.0×	13.8k 0.9×	8.9k 0.7×	4.8k 0.6×	330	37.3k
Armando E. Giuliano United States	76	18.6k 0.8×	10.2k 0.6×	13.0k 0.8×	10.4k 0.8×	2.5k 0.3×	330	28.6k

Countries citing papers authored by Kelly K. Hunt

Since Specialization

Citations

This map shows the geographic impact of Kelly K. Hunt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kelly K. Hunt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kelly K. Hunt more than expected).

Fields of papers citing papers by Kelly K. Hunt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kelly K. Hunt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kelly K. Hunt. The network helps show where Kelly K. Hunt may publish in the future.

Co-authorship network of co-authors of Kelly K. Hunt

This figure shows the co-authorship network connecting the top 25 collaborators of Kelly K. Hunt. A scholar is included among the top collaborators of Kelly K. Hunt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kelly K. Hunt. Kelly K. Hunt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Huang, Monica L., Deanna L. Lane, Rosalind P. Candelaria, et al.. (2024). Defining Breast Cryoablation Treatment Success: A Guide for the Curative and Palliative Treatment of Breast Cancer. Academic Radiology. 31(12). 4759–4771. 1 indexed citations

Wanis, Kerollos Nashat, Alycia So, Alexa Glencer, et al.. (2024). The Prevalence of Sentinel Lymph Node Positivity and Implications for the Utility of Frozen Section Diagnosis Following Neoadjuvant Systemic Therapy in Patients with Clinically Node-Negative HER2-Positive or Triple-Negative Breast Cancer. Annals of Surgical Oncology. 31(11). 7339–7346.

Checka, Cristina M., et al.. (2023). Evaluation of a Surgical Navigation System for Localization and Excision of Nonpalpable Lesions in Breast and Axillary Surgery. The Breast Journal. 2023. 1–7. 1 indexed citations

Suman, Vera J., Lili Du, Tanya L. Hoskin, et al.. (2022). Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031). Clinical Cancer Research. 28(15). 3287–3295. 12 indexed citations

Ha, Min Jin, Akshara Singareeka Raghavendra, Nicole M. Kettner, et al.. (2022). Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2− metastatic breast cancer patients compared to endocrine therapy alone in the second‐line setting: A large institutional study. International Journal of Cancer. 150(12). 2025–2037. 27 indexed citations

Cynthia, X., Vera J. Suman, A. Marilyn Leitch, et al.. (2020). ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106.. Journal of Clinical Oncology. 38(15_suppl). 504–504. 27 indexed citations

Park, Ko Un, Min Yi, Isabelle Bedrosian, et al.. (2019). Opioid Use after Breast-Conserving Surgery: Prospective Evaluation of Risk Factors for High Opioid Use. Annals of Surgical Oncology. 27(3). 730–735. 13 indexed citations

Fujii, T., Takahiro Kogawa, Wanli Dong, et al.. (2017). Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Annals of Oncology. 28(10). 2420–2428. 110 indexed citations

Carey, Jason P.W., Cansu Karakaş, Tuyen Bui, et al.. (2017). Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. Cancer Research. 78(3). 742–757. 103 indexed citations

10.

Doostan, Iman, Cansu Karakaş, Matthew J. Ellis, et al.. (2017). Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. Clinical Cancer Research. 23(23). 7288–7300. 35 indexed citations

11.

Mittendorf, Elizabeth A. & Kelly K. Hunt. (2015). Breast Cancer Immunotherapy: Is It Ready for Prime Time?. 11(9). 4 indexed citations

12.

Huo, Lei, Jinxia Zhang, Michael Z. Gilcrease, et al.. (2012). Gross cystic disease fluid protein‐15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple‐negative breast cancer. Histopathology. 62(2). 267–274. 35 indexed citations

13.

Hunt, Kelly K., Khazi M. Nayeemuddin, Roland L. Bassett, et al.. (2011). Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers. Breast Cancer Research and Treatment. 131(1). 41–48. 46 indexed citations

14.

Bu, Dawei, Venetia Sarode, Raheela Ashfaq, et al.. (2011). Tamoxifen Downregulates Ets Oncogene Family Members ETV4 and ETV5 in Benign Breast Tissue: Implications for Durable Risk Reduction. Cancer Prevention Research. 4(11). 1852–1862. 13 indexed citations

15.

Kuerer, Henry M., Aman U. Buzdar, Elizabeth A. Mittendorf, et al.. (2010). Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer. 117(1). 39–47. 48 indexed citations

16.

Leeuwen, Barbara L. van, Kari M. Rosenkranz, Liang Feng, et al.. (2010). The effect of under-treatment of breast cancer in women 80 years of age and older. Critical Reviews in Oncology/Hematology. 79(3). 315–320. 65 indexed citations

17.

Bagheri‐Yarmand, Rozita, Anna Biernacka, Kelly K. Hunt, & Khandan Keyomarsi. (2010). Low Molecular Weight Cyclin E Overexpression Shortens Mitosis, Leading to Chromosome Missegregation and Centrosome Amplification. Cancer Research. 70(12). 5074–5084. 45 indexed citations

18.

Delk, Nikkí A., Kelly K. Hunt, & Khandan Keyomarsi. (2009). Altered Subcellular Localization of Tumor-Specific Cyclin E Isoforms Affects Cyclin-Dependent Kinase 2 Complex Formation and Proteasomal Regulation. Cancer Research. 69(7). 2817–2825. 36 indexed citations

19.

Şahin, Ayşegül A., et al.. (2008). Cyclin E deregulation is an early event in the development of breast cancer. Breast Cancer Research and Treatment. 115(3). 651–659. 28 indexed citations

20.

Buzdar, Aman U., Nuhad K. Ibrahim, Daniel J. Booser, et al.. (2005). Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer. Journal of Clinical Oncology. 23(16). 3676–3685. 867 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact